Comparing Bortezomib-Bendamustine-Melphalan and High-Dose Melphalan in Stem Cell Transplant for Relapsed Multiple Myeloma

What this Trial Is About

This research aims to evaluate and compare the effectiveness and safety of two conditioning regimens, bortezomib-bendamustine-melphalan BBM and high-dose melphalan HDM, in patients with relapsed multiple myeloma undergoing autologous hematopoietic stem cell transplantation ASCT. The study is a retrospective single center cohort analysis conducted at Uppsala University Hospital, reviewing treatments given from 2011 to 2018 and comparing them to periods before and after. Patients who received BBM or HDM conditioning as part of their second ASCT after relapse will be studied using data from electronic medical records and the Swedish Cancer Registry. The study compares time to next treatment TNT between the first and second ASCT for each patient and evaluates differences in efficacy and severe adverse events between the two conditioning regimens. Subgroup analyses include factors like prior treatment response, maintenance therapies, and high-risk genetic features. Participants medical records will be systematically analyzed for outcomes such as time to next treatment, progression-free survival, overall survival, depth of response, treatment-related mortality, neutropenia duration, engraftment time, hospitalization length, and serious adverse events up to 100 days after the second ASCT. The study involves monitoring these outcomes retrospectively over periods ranging from days to years after transplantation.

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma